| Filed On | Filing |
|---|---|
| 10 Jun 2026 | 8-K/A: Financial Statements and Exhibits |
| 28 Sep 2023 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported on the Original Form 8-K, in an advisory vote held at the Annual Meeting on the Say-on-Frequency Proposal, the Company’s stockholders expressed their preference for a Say-on-Pay Vote to be conducted every year. The... |
| 20 Jul 2022 |
8-K/A: Results of Operations and Financial Condition
Cambridge, Mass. — July 20, 2022 — Biogen Inc. (Nasdaq: BIIB) today reported second quarter 2022 financial results. |
| 12 Feb 2013 |
8-K/A: Financial Statements and Exhibits
*****Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. |
| 24 Jul 2012 |
8-K/A: Results of Operations and Financial Condition
— Preparing for BG-12 Launch and Four Phase 3 Data Readouts in Next Nine Months — |
| 01 Feb 2011 |
8-K/A: Results of Operations and Financial Condition
Correcting and Replacing Biogen Idec Reports Full Year and Fourth Quarter 2010 Results 25% Non-GAAP and 18% GAAP Diluted EPS Growth Over Prior Year |
| 12 Jan 2004 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial statements give effect to the merger of the Registrant and Biogen in a transaction to be accounted for as a purchase with the Registrant treated as the acquirer. The unaudite... |
| 25 Nov 2003 |
8-K/A: Changes in Registrant's Certifying Accountant
We were previously principal accountants for IDEC Pharmaceuticals Corporation and subsidiaries (IDEC) and, under the date of January 29, 2003, we reported on the consolidated financial statements of IDEC as of and for the years ended Dec... |
| 03 Oct 2003 |
8-K/A: Other Events
QuickLinks -- Click here to rapidly navigate through this document |
Loading...